A recent meta-analysis [69] of randomized controlled trials evaluating the effects of insulin versus oral hypoglycaemic agents (OHAs) on all-cause mortality and CV outcomes in patients with T2DM did not show any superiority for insulin therapy concerning all-cause mortality (RR = 1.00; 95 % CI 0.93–1.07), CV death (RR = 1.00; 95 % CI 0.91–1.09), myocardial infarction (RR = 1.04; 95 % CI 0.93–1.16), angina (RR = 0.97; 95 % CI 0.88–1.06), sudden death (RR = 1.02; 95 % CI 0.66–1.56), or stroke (RR = 1.01; 95 % CI 0.88–1.15). This evidence concerns the gene INS and myocardial infarction.